3.70
price down icon2.37%   -0.09
after-market After Hours: 4.20 0.50 +13.51%
loading
Titan Pharmaceuticals Inc De stock is traded at $3.70, with a volume of 2,564. It is down -2.37% in the last 24 hours and down -3.90% over the past month. Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
See More
Previous Close:
$3.79
Open:
$3.75
24h Volume:
2,564
Relative Volume:
0.08
Market Cap:
$3.25M
Revenue:
$61,000
Net Income/Loss:
$-5.46M
P/E Ratio:
-0.5657
EPS:
-6.54
Net Cash Flow:
$-6.76M
1W Performance:
-0.80%
1M Performance:
-3.90%
6M Performance:
-4.00%
1Y Performance:
-46.92%
1-Day Range:
Value
$3.70
$4.11
1-Week Range:
Value
$3.53
$4.11
52-Week Range:
Value
$3.03
$14.80

Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile

Name
Name
Titan Pharmaceuticals Inc De
Name
Phone
(650) 244-4990
Name
Address
400 OYSTER POINT BLVD, SAN FRANCISCO
Name
Employee
4
Name
Twitter
@titanpharma
Name
Next Earnings Date
2024-06-28
Name
Latest SEC Filings
Name
TTNP's Discussions on Twitter

Compare TTNP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TTNP
Titan Pharmaceuticals Inc De
3.70 3.25M 61,000 -5.46M -6.76M -6.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-26-19 Initiated Maxim Group Buy
Nov-10-17 Downgrade ROTH Capital Buy → Neutral

Titan Pharmaceuticals Inc De Stock (TTNP) Latest News

pulisher
Apr 14, 2025

US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted' - Benzinga

Apr 14, 2025
pulisher
Apr 11, 2025

Titan Pharma Lands Crucial $1M Backing: Inside the Strategic Investment Deal - Stock Titan

Apr 11, 2025
pulisher
Apr 11, 2025

Clinical Data: Nika's ITV-1 Drug Demonstrates Breakthrough Effects in Multiple Diseases - Stock Titan

Apr 11, 2025
pulisher
Apr 11, 2025

Nasdaq Delisting Risk Eliminated: Dogwood Therapeutics Secures Future with $17.5M War Chest - Stock Titan

Apr 11, 2025
pulisher
Apr 10, 2025

Conduit Pharma Signals Stock Undervalued: Announces $1M Buyback as Phase II Trials Near - Stock Titan

Apr 10, 2025
pulisher
Apr 09, 2025

Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan

Apr 09, 2025
pulisher
Apr 08, 2025

Failed Merger Forces Vincerx Pharma to Begin Company Wind-Down: What's Next for Investors? - Stock Titan

Apr 08, 2025
pulisher
Apr 04, 2025

Arrowhead Pharmaceuticals Expands Team with 34,190 RSU Grants to New Hires - Stock Titan

Apr 04, 2025
pulisher
Apr 04, 2025

Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan

Apr 04, 2025
pulisher
Apr 03, 2025

Strategic $2.5M Investment Values Mental Health Clinic Network at $50M: Major Expansion Ahead - Stock Titan

Apr 03, 2025
pulisher
Apr 02, 2025

Key Investor Update: Lexicon Pharma Takes Stage at Elite Needham Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Apr 01, 2025

Citius Secures Strategic $2M Funding to Accelerate LYMPHIR LaunchKey Details Revealed - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan

Mar 31, 2025
pulisher
Mar 27, 2025

Ironwood Pharma Gets 60-Day Window to Resolve Nasdaq Compliance Issue - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Actinium Reveals 3 Breakthrough Programs Targeting Billion-Dollar Markets at Mar-a-Lago Update - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Major Cancer Breakthrough: Zentalis Reveals New Azenosertib Data Across Multiple Tumor Types - Stock Titan

Mar 25, 2025
pulisher
Mar 23, 2025

$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan

Mar 23, 2025
pulisher
Mar 21, 2025

Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post

Mar 21, 2025
pulisher
Mar 20, 2025

Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan

Mar 19, 2025
pulisher
Mar 13, 2025

Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - Stock Titan

Mar 13, 2025
pulisher
Mar 12, 2025

NRx Pharmaceuticals Readies Major Financial Update: Full Year Results and Strategic Outlook Coming March 17 - Stock Titan

Mar 12, 2025
pulisher
Mar 11, 2025

Endo's $99M Strategic Sale: International Pharma Division Goes to Knight Therapeutics - Stock Titan

Mar 11, 2025
pulisher
Mar 10, 2025

Acurx Raises $1.1M in Direct Offering to Advance Antibiotics Pipeline - StockTitan

Mar 10, 2025
pulisher
Mar 07, 2025

Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan

Mar 07, 2025
pulisher
Mar 07, 2025

Will NovaBay Survive? Crucial Stockholder Vote Could Determine Company's Fate - StockTitan

Mar 07, 2025
pulisher
Mar 06, 2025

Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - Stock Titan

Mar 06, 2025
pulisher
Mar 05, 2025

How Will CTT Pharmaceuticals' OTCQB Upgrade Transform Its Market Presence? - StockTitan

Mar 05, 2025
pulisher
Mar 04, 2025

Milestone Pharmaceuticals Awards 94,000 Stock OptionsWhat This Means for Shareholder Value - Stock Titan

Mar 04, 2025
pulisher
Mar 03, 2025

Elite Pharmaceuticals Triples Manufacturing Potential With High-Speed Facility Launch - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

When Will ARS Pharmaceuticals Reveal Its 2024 Financial Performance? - Stock Titan

Mar 03, 2025
pulisher
Feb 28, 2025

Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - Stock Titan

Feb 28, 2025
pulisher
Feb 27, 2025

Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

When Can Investors Hear Milestone Pharma's Next Strategic Update? Key Conference Date Revealed - Stock Titan

Feb 27, 2025
pulisher
Feb 26, 2025

Can This New Estée Lauder Partnership Transform How Your Skin Ages? - Stock Titan

Feb 26, 2025
pulisher
Feb 25, 2025

Will Universe Pharmaceuticals Survive Nasdaq's Latest Delisting Threat? - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Adial's Addiction Treatment Clears Critical FDA Hurdle Ahead of 2025 Phase 3 Trials - Stock Titan

Feb 25, 2025
pulisher
Feb 24, 2025

Can KalVista's March Conference Circuit Signal Major Pipeline Updates? - Stock Titan

Feb 24, 2025
pulisher
Feb 21, 2025

Will SXTC's Share Consolidation Save Its Nasdaq Listing? Key Dates Revealed - StockTitan

Feb 21, 2025
pulisher
Feb 20, 2025

Can This $430M Pharma Merger Create the Next Women's Health Giant? - StockTitan

Feb 20, 2025
pulisher
Feb 20, 2025

Can This 1-for-5 Reverse Split Save 60 Degrees Pharma's Nasdaq Status? - StockTitan

Feb 20, 2025
pulisher
Feb 20, 2025

Failed Merger: Why HOOKIPA Pharma Walked Away from Poolbeg Deal - Stock Titan

Feb 20, 2025
pulisher
Feb 19, 2025

Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - Stock Titan

Feb 19, 2025
pulisher
Feb 18, 2025

Major Capital Raise: Petros Pharmaceuticals Locks $9.6M Financing DealStrategic Move or Dilution Risk? - Stock Titan

Feb 18, 2025
pulisher
Feb 14, 2025

Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M - StockTitan

Feb 14, 2025
pulisher
Feb 13, 2025

Elite Pharma Q3 Results Reveal Sharp Profit Decline: Holiday Delays Impact Performance - StockTitan

Feb 13, 2025
pulisher
Feb 13, 2025

Major Lupus Breakthrough? Conduit Teams Up with Charles River for Game-Changing Treatment Study - Stock Titan

Feb 13, 2025
pulisher
Feb 11, 2025

Milestone's CARDAMYST Launch Roadmap: Key Details Coming for $1B PSVT Market Opportunity - Stock Titan

Feb 11, 2025
pulisher
Feb 10, 2025

Elite Pharmaceuticals (ELTP) Earnings Preview: Q3 Performance & Strategic Roadmap Unveiling Feb 14 - StockTitan

Feb 10, 2025
pulisher
Feb 10, 2025

Opioid Use Disorders Market to Reach USD 8.8 Billion by - GlobeNewswire

Feb 10, 2025

Titan Pharmaceuticals Inc De Stock (TTNP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):